Skip to main content
Hualan Biological Engineering Inc. logo

Hualan Biological Engineering Inc. — Investor Relations & Filings

Ticker · 002007 ISIN · CNE000001JN8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,527 across all filing types
Latest filing 2015-03-27 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 002007

About Hualan Biological Engineering Inc.

https://www.hualanbio.com

Hualan Biological Engineering Inc. is a biopharmaceutical enterprise specializing in the research, development, production, and commercialization of blood products and vaccines. The company’s portfolio is divided into two primary segments: plasma-derived therapeutics and viral vaccines. Key blood products include human albumin, intravenous immunoglobulin (IVIG), human coagulation factor VIII, and prothrombin complex. In the vaccine sector, the company produces seasonal influenza vaccines, including quadrivalent formulations, as well as hepatitis B and rabies vaccines. Hualan Biological Engineering operates advanced manufacturing facilities and plasma collection centers, focusing on high-quality standards and technological innovation in recombinant protein drugs and monoclonal antibodies to address critical medical needs in immunology, hematology, and infectious disease prevention.

Recent filings

Filing Released Lang Actions
2014年年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled as an "审计报告" (Audit Report) for 华兰生物工程股份有限公司 covering the fiscal year from January 1, 2014 to December 31, 2014. It includes detailed audit opinions from 大华会计师事务所 (Da Hua Certified Public Accountants), financial statements such as consolidated and parent company balance sheets, income statements, cash flow statements, and equity changes, along with notes to the financial statements. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement. The presence of an auditor's opinion and detailed financial statements confirms this is a standalone audit report rather than a full annual report (10-K) or other filing. Therefore, the document fits the definition of an Audit Report / Information (AR). FY 2014
2015-03-27 Chinese
2014年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Control Evaluation Report" for the year 2014 by 华兰生物工程股份有限公司. It discusses the company's internal control systems, evaluation scope, methodology, and conclusions about the effectiveness of internal controls over financial reporting and non-financial reporting. It references regulatory frameworks and standards related to internal control but does not present full financial statements or detailed financial performance data. The document is a standalone report focused on internal control evaluation, not a full annual report or audit report. It is not an announcement or a brief notice but a substantive report on internal control evaluation. Therefore, it fits best under the category of Audit Report / Information (AR), which includes standalone audit reports and internal control evaluation results, excluding full annual reports. FY 2014
2015-03-27 Chinese
第五届监事会第十六次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of 华兰生物工程股份有限公司 regarding their 16th meeting of the 5th Supervisory Board. It includes approval of the 2014 Supervisory Board Work Report, the 2014 Annual Report and summary, the 2014 Financial Final Accounts Report, profit distribution plan, internal control self-evaluation report, and other governance matters. The document is short (1293 characters) and primarily announces the passing of various reports and proposals rather than containing the full reports themselves. It is not a full Annual Report (10-K) or Interim Report (IR), nor is it a Management Report (MDA). It is also not a voting result announcement (DVA) since it is a Supervisory Board meeting resolution, not a shareholder vote. The document fits best as a Regulatory Filing (RNS) because it is a formal announcement of Supervisory Board meeting resolutions and approvals without the full reports attached or included.
2015-03-27 Chinese
未来三年（2015-2017年）股东回报规划
Notice of Dividend Amount Classification · 90% confidence The document is a formal statement from the company's board regarding a shareholder return plan for the years 2015-2017. It outlines principles, considerations, and mechanisms for dividend distribution and shareholder returns. It is not a financial report, earnings release, or regulatory filing but a planning document related to dividends and shareholder returns. It does not announce voting results, changes in management, or legal proceedings. It is a forward-looking shareholder return plan, which fits best under Notice of Dividend Amount (DIV) as it details dividend policy and payment approach over multiple years.
2015-03-27 Chinese
内部控制规则落实自查表
Audit Report / Information Classification · 95% confidence The document is titled as an internal control self-assessment checklist for a company (华兰生物工程股份有限公司) and dated March 28, 2015. It details the company's internal control procedures, audit committee operations, information disclosure controls, insider trading controls, fundraising controls, related party transactions, external guarantees, major investments, and other important matters. There are no financial statements, no earnings data, no management discussion of financial results, no voting results, no legal proceedings, no capital changes, and no mention of report publication or regulatory filings. The document is a detailed internal control report, which aligns with the category of Audit Report / Information (AR), as it relates to internal audit and control procedures and compliance. The document length (7909 characters) and content support it being a standalone audit/internal control report rather than a brief announcement or certification. Therefore, the best classification is AR with high confidence. FY 2014
2015-03-27 Chinese
2014年度社会责任报告书
Environmental & Social Information Classification · 100% confidence The document is titled '2014 年度社会责任报告书' which translates to '2014 Annual Social Responsibility Report'. It details the company's activities and performance related to social responsibility, including environmental protection, employee welfare, stakeholder engagement, and sustainable development for the year 2014. The content focuses on Environmental, Social, and Governance (ESG) factors and the company's social responsibility initiatives rather than financial performance or regulatory compliance. The length of the document (8510 characters) and the detailed content confirm it is a full report rather than a brief announcement. Therefore, the document fits the category of Environmental & Social Information (SR).
2015-03-27 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.